The estimated Net Worth of James B Nelson is at least $1.32 Million dollars as of 27 April 2018. Mr. Nelson owns over 192,308 units of Co-Diagnostics Inc stock worth over $1,150,283 and over the last 9 years he sold CODX stock worth over $126,625. In addition, he makes $45,833 as Independent Director at Co-Diagnostics Inc.
James has made over 2 trades of the Co-Diagnostics Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently he sold 12,500 units of CODX stock worth $126,625 on 13 January 2021.
The largest trade he's ever made was exercising 192,308 units of Co-Diagnostics Inc stock on 27 April 2018 worth over $50,000. On average, James trades about 13,654 units every 66 days since 2016. As of 27 April 2018 he still owns at least 912,923 units of Co-Diagnostics Inc stock.
You can see the complete history of Mr. Nelson stock trades at the bottom of the page.
James B. Nelson serves as Independent Director of the Company. He is the retired Chairman and CEO of Sunworks, Inc., a NASDAQ traded commercial, agriculture, and residential solar Integrator which he helped found in October 2010. Mr. Nelson currently serves as strategic advisor to three other publicly traded companies. Jim has spent most of his career working in private equity as a general partner with Peterson Partners and with Millennial Capital Partners. In addition to his investment and financial responsibilities, he served as CEO of two of his firms’ portfolio companies. Prior to his years in private equity, Mr. Nelson served as Vice President of Marketing at Banana Republic, where he managed company-wide marketing, as well as the company’s international expansion initiative. He was also general manager for Banana Republic’s catalog division. He was Vice President of Marketing and Corporate Development at Saga Corporation, a multi-billion-dollar food service company. Jim began his executive career over 35 years ago at Bain and Company, a business strategy consulting firm, where he managed teams of consultants on four continents. Mr. Nelson received his MBA from Brigham Young University, where he graduated summa cum laude and was named the Outstanding Master of Business Administration Graduate. Mr. Nelson’s advice to the Board of Directors from his experiences as a chief executive officer and strategic advisor shall be useful to the Board of Directors.
As the Independent Director of Co-Diagnostics Inc, the total compensation of James Nelson at Co-Diagnostics Inc is $45,833. There are 5 executives at Co-Diagnostics Inc getting paid more, with Dwight H. Egan having the highest compensation of $676,875.
James Nelson is 67, he's been the Independent Director of Co-Diagnostics Inc since 2019. There are 3 older and 6 younger executives at Co-Diagnostics Inc. The oldest executive at Co-Diagnostics Inc is Richard Serbin, 75, who is the Independent Director.
James's mailing address filed with the SEC is 2401 S. FOOTHILL DRIVE SUITE D, , SALT LAKE CITY, UT, 84109.
Over the last 7 years, insiders at Co-Diagnostics Inc have traded over $2,459,090 worth of Co-Diagnostics Inc stock and bought 8,205 units worth $11,819,010 . The most active insiders traders include Reed L Benson, James B Nelson, and Dwight H Egan. On average, Co-Diagnostics Inc executives and independent directors trade stock every 79 days with the average trade being worth of $38,652. The most recent stock trade was executed by Brian Lee Brown on 20 March 2023, trading 3,000 units of CODX stock currently worth $5,700.
co-diagnostics, inc. is a molecular diagnostics company that has acquired certain unique, patented diagnostic testing technology. a utah corporation headquartered in sandy, utah, its primary business is to commercialize its unique, patented technology through sales, development and licensing. the technology is embodied in three patent applications and certain trade secrets, which make dna testing for diseases faster, higher in performance, and more cost efficient than traditional technologies of the past. the company has undertaken completely innovative approaches to develop novel molecular technologies using biophysical models and statistical bioinformatics. it has successfully developed and commercialized a series of assays in the infectious disease area to demonstrate the capability of its technology. the technology on which the inventions are based were created by reference to certain mathematical models invented, designed and refined by dr. brent c. satterfield. the inventions are
Co-Diagnostics Inc executives and other stock owners filed with the SEC include: